- Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y, Nakagomi T, Nagakubo Y, Goto T, Omata M.
Sci Rep. 2024;14(1):1594.
- In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I, Kagami K, Nozaki T, Hirotsu Y, Amemiya K, Oyama T, Omata M.
Am J Surg Pathol. 2024;48(3):374-375.
- Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection.
Hirotsu Y, Takatori M, Mochizuki H, Omata M.
Vaccine X. 2024;17:100433.
- Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer.
Nozaki T, Sakamoto I, Kagami K, Amemiya K, Hirotsu Y, Mochizuki H, Omata M.
J Gynecol Oncol. 2024;35(4):e55.
- Changes in Viral Dynamics Following the Legal Relaxation of COVID-19 Mitigation Measures in Japan From Children to Adults: A Single Center Study, 2020-2023.
Hirotsu Y, Nagakubo Y, Maejima M, Shibusawa M, Hosaka K, Sueki H, Mochizuki H, Omata M.
Influenza Other Respir Viruses. 2024;18(3):e13278.
- Liquid biopsy of wash samples obtained via endoscopic ultrasound-guided fine-needle biopsy: Comparison with liquid biopsy of plasma in pancreatic cancer.
Ohyama H, Hirotsu Y, Amemiya K, Amano H, Hirose S, Oyama T, Iimuro Y, Kojima Y, Mikata R, Mochizuki H, Kato N, Omata M.
Diagn Cytopathol. 2024;52(6):325-331.
- The efficacy of bile liquid biopsy in the diagnosis and treatment of biliary tract cancer.
Miura Y, Ohyama H, Mikata R, Hirotsu Y, Amemiya K, Mochizuki H, Ikeda J, Ohtsuka M, Kato N, Omata M.
J Hepatobiliary Pancreat Sci. 2024;31(5):329-338.
- Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y, Hirotsu Y, Yoshino M, Amemiya K, Saito R, Kakizaki Y, Tsutsui T, Miyashita Y, Goto T, Omata M.
Sci Rep. 2024;14(1):12480.
- Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers-Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test.
Miyashita Y, Hirotsu Y, Nagakubo Y, Kobayashi H, Kawaguchi M, Hata K, Saito R, Kakizaki Y, Tsutsui T, Oyama T, Omata M.
JTO Clin Res Rep. 2024;5(6):100679.
- Dynamic change of cancer genome profiling in metachronous bilateral breast cancer with BRCA pathogenic variant.
Kimura A, Nakagomi H, Inoue M, Oka T, Hirotsu Y, Amemiya K, Mochizuki H, Oyama T, Omata M.
Int Cancer Conf J. 2024;13(3):193-198.
